Dr. Lior Shaltiel reports

AUSTRALIAN PATENT GRANTED TO NUREXONE COVERING STEM CELL-DERIVED EXOSOME PRODUCTION

A patent covering the "production of extracellular vesicles from stem cells" has been granted to Nurexone Biologic Inc. by IP Australia.

The patent, Australian patent No. 2020303456, was granted on April 23, 2026, and is held by Technion Research and Development Foundation Ltd. The patent relates to technology licensed exclusively to Nurexone and is expected to remain in force until June 10, 2040, subject to the payment of applicable fees.

"Consistency is one of the most important value drivers in biomanufacturing," said Dr. Lior Shaltiel, chief executive officer of Nurexone. "This patent grant supports our strategy to protect core technologies enabling the scalable, reproducible production of high-quality exosomes required for therapeutic development. As we take steps to build manufacturing capacity, including our recently announced LOI with U.S.-based BioXtek, we are also working in parallel to protect the technologies to support scalable and reliable exosome production."

The patent further expands Nurexone's international patent family, covering the production of extracellular vesicles from stem cells. It follows previously announced patent grants in Israel and the United States, with additional applications currently under examination in other jurisdictions. This development reflects the company's strategy to secure broad, strategically aligned intellectual property protection across key commercial, regulatory and manufacturing markets in support of its exosome biomanufacturing technology.

Scientific presentation on ExoPTEN's regenerative potential in optic nerve damage

The use of Nurexone's ExoPTEN in models of damaged optic nerves will be featured in an upcoming scientific presentation by Dr. Ifat Sher and Prof. Ygal Rotenstreich of the Goldschleger Eye Institute at Sheba Medical Center. The presentation will take place at ISCEV@Denver, a meeting of the Western Hemisphere Division of the International Society for Clinical Electrophysiology of Vision, held ahead of the ARVO annual meeting. Titled "ERG as a Functional Biomarker for Monitoring Optic Nerve Regeneration in a Rat Model of Optic Nerve Crush," the presentation is scheduled for May 2, 2026, at the Colorado Convention Center in Denver. The research was conducted as part of a collaborative program between Nurexone and Sheba Medical Center focused on preclinical evaluation of optic nerve regeneration therapies.

About Nurexone Biologic Inc.

Nurexone is a TSX Venture Exchange-, OTCQB- and Frankfurt Stock Exchange-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. Regulatory milestones, including obtaining the orphan drug designation, facilitates the company's road map toward clinical trials in the United States and Europe. Commercially, the company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Nurexone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.

We seek Safe Harbor.